Dr. Abraham Heifets is CEO and Co-Founder of Atomwise, where he and Co-Founder Dr. Izhar Wallach invented the use of deep convolutional neural networks for drug discovery.

Dr. Heifets was a Massey Fellow at the University of Toronto—a center for AI innovation—and a Fellow of the Ontario Brain Institute. His doctoral work applied machine learning and classical AI techniques to organic synthesis planning, a long-standing challenge in chemistry. His vision of AI bringing better, safer and more potent drugs to patients was featured in the July 2019 Moonshot issue of Newsweek.

Dr. Heifets is a thought-leader on the use of AI for drug discovery and is an author on 24 papers, patents and patent applications. Dr. Heifets has presented his work to the U.S. GAO, the National Institutes of Health, the American Chemical Society, and the Association for the Advancement of Artificial Intelligence.

Artificial Intelligence, Technology, Science, STEM, Computer Science, Data, Science and Technology Professionals, Neuroscience, Neuropsychology, Neurological Disorder Chemistry,